These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26939612)

  • 1. Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era.
    Galicia-Hernández G; Parra-Salcedo F; Ugarte-Martínez P; Contreras-Yáñez I; Ponce-de-León A; Pascual-Ramos V
    Clin Exp Rheumatol; 2016; 34(2):261-9. PubMed ID: 26939612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity.
    Parra-Salcedo F; Contreras-Yáñez I; Elías-López D; Aguilar-Salinas CA; Pascual-Ramos V
    Arthritis Res Ther; 2015 Feb; 17(1):34. PubMed ID: 25889060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
    Curtis JR; Winthrop K; O'Brien C; Ndlovu MN; de Longueville M; Haraoui B
    Arthritis Res Ther; 2017 Dec; 19(1):276. PubMed ID: 29246162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1.
    Weaver A; Troum O; Hooper M; Koenig AS; Chaudhari S; Feng J; Wenkert D
    J Rheumatol; 2013 Aug; 40(8):1275-81. PubMed ID: 23772079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
    Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
    Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs.
    Contreras-Yáñez I; Rull-Gabayet M; Pascual-Ramos V
    Clin Exp Rheumatol; 2012; 30(3):402-8. PubMed ID: 22510514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis.
    Contreras-Yáñez I; Pascual-Ramos V
    BMC Musculoskelet Disord; 2017 Jul; 18(1):321. PubMed ID: 28754110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.
    Contreras-Yáñez I; Pascual-Ramos V
    Arthritis Res Ther; 2015 Jul; 17(1):177. PubMed ID: 26162892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Dutmer EA; Brus HL; Houtman NM; van de Laar MA; van Riel PL
    Rheumatology (Oxford); 2013 Jun; 52(6):1052-7. PubMed ID: 23365147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis.
    Widdifield J; Bernatsky S; Paterson JM; Gunraj N; Thorne JC; Pope J; Cividino A; Bombardier C
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):353-61. PubMed ID: 22833532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study.
    Hernández-Cruz B; Cardiel MH; Villa AR; Alcocer-Varela J
    J Rheumatol; 1998 Oct; 25(10):1900-7. PubMed ID: 9779842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study.
    Curtis JR; Xie F; Chen L; Saag KG; Yun H; Muntner P
    Ann Rheum Dis; 2018 Mar; 77(3):386-392. PubMed ID: 29269418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
    Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
    Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
    Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.